Forskning ved Københavns Universitet - Københavns Universitet

Forside

Chimeric antigen receptor-T-cellebehandling

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Although treatment of haematological cancer has improved significantly during the latest decades, the prognosis is poor in case of relapse or refractory disease. This review describes the chimeric antigen receptor (CAR) T-cell therapy, which has emerged as a new promising treatment principle, in which the patient's own T-cells are genetically modified to recognise cancer cells. The possible side effects are usually only transient. A commercial CD19 CAR T-cell product has recently been approved as treatment for acute lympho-blastic leukaemia in children and young adults in Denmark, and a non-commercial CAR T-cell production is being established.

OriginalsprogDansk
ArtikelnummerV05190309
TidsskriftUgeskrift for Laeger
Vol/bind181
Udgave nummer20A
Antal sider5
ISSN0041-5782
StatusUdgivet - 2019

ID: 238526118